Plant Name: Arum ternatum thunb
Taxonomic Information:
Plant ID: NPO4737
Plant Latin Name: Arum ternatum thunb
Taxonomy Genus: Arum
Taxonomy Family: Araceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; ADORA3; FFAR4; | |
| GRM1; GRM8; | |
| BLM; TK1; ALOX12; ALOX15; USP2; APEX1; | |
| GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; | |
| GABRR1; | |
| TRPV1; | |
| CA2; CA14; | |
| PPARA; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| NFKB1; | |
| FUT7; | |
| KMT2A; | |
| SLC1A1; | |
| LMNA; FABP3; FABP5; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 1.921E-10 | 8.366E-07 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 1.077E-09 | 2.930E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 2.978E-09 | 5.896E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 5.930E-08 | 6.796E-05 | GRIK1, GRIK3, GRIK5 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 1.072E-07 | 1.111E-04 | GABRR1, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, TRPV1 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.729E-07 | 1.637E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 4.956E-07 | 4.316E-04 | GRIK3, GRM1, GRM8 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.253E-06 | 1.322E-03 | ADORA3, FFAR1, FFAR4, GABRR1, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, GRM1, GRM8, PPARA, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 2.308E-06 | 1.322E-03 | GABRR1, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, TRPV1 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.377E-06 | 1.599E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.377E-06 | 1.599E-03 | ALOX12, ALOX15 |
| BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 4.298E-06 | 1.872E-03 | GRIK1, GRIK3, GRM1, GRM8 |
| BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 1.032E-05 | 3.685E-03 | BLM, CA2, GRM1, KMT2A, LMNA, MMP2, NFKB1, PPARA, TRPV1, USP2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.012E-05 | 3.685E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.012E-05 | 3.685E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.026E-05 | 3.685E-03 | CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.122E-05 | 3.941E-03 | ALOX12, ALOX15, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.329E-05 | 4.523E-03 | FABP3, FABP4, FABP5 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.022E-05 | 5.869E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 2.022E-05 | 5.869E-03 | GRIA2, GRIA4 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 3.365E-05 | 7.880E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 4.408E-05 | 9.696E-03 | MMP1, MMP2, MMP9, TRPV1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 2.301E-11 | 2.268E-09 | GRIA2, GRIK5, SLC1A1, GRM8, GRIK3, GRIK1, GRM1, GRIA4 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 4.087E-11 | 2.268E-09 | GRIA2, GABRR1, GRIK5, ADORA3, GRM8, GRIK3, GRIK1, TRPV1, GRM1, GRIA4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.463E-07 | 5.414E-06 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 3.187E-05 | 7.076E-04 | GRIA2, GABRR1, GRM1, GRIA4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.895E-05 | 5.259E-04 | CYP1A2, ALOX15, CYP3A4 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05033 | Nicotine addiction | 5.055E-05 | 8.637E-04 | GRIA2, GABRR1, GRIA4 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 5.447E-05 | 8.637E-04 | MMP1, MMP2, MMP9 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.544E-04 | 2.142E-03 | CYP1A2, CYP1B1, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.366E-04 | 4.038E-03 | GRIA2, PPARA, NFKB1, GRIA4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.055E-04 | 3.768E-03 | CYP1A2, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.461E-04 | 6.370E-03 | MMP2, MMP9, GRM1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.302E-04 | 4.038E-03 | CYP1A2, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.212E-04 | 4.038E-03 | CA2, CA14 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA2; GRIA4; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRM1; GRIK1; TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TK1; MMP9; MMP2; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TK1; MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; TK1; ADORA3; MMP9; MMP2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TK1; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRM1; GRIK1; TRPV1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRM1; GRIK1; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
